Teduglutide – USA

Teduglutide – USA

On Nov 15, 2017, Court of appeal for the federal circuit in a non-precedential opinion affirmed the decision of paten trial & appellate board (PTAB) which found formulation patent of Teduglutide (Gattex) invalid. Previously PTAB found NPS pharmaceutical’s U.S. Patent Number 7,056,886 invalid under obviousness in two IPR proceedings (IPR2015-00990 & IPR2015-01093).

US’886 claims GLP-2 (teduglutide) composition with histidine, phosphate buffer &  mannitol /sucrose. PTAB in its decision held that use of histidine & mannitol was well known in protein formulation and experimentation needed to confirm successful application with GLP-2 analog was nothing more than routine practice.
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved